US regulatory status: approved. Molecular target: ATP-sensitive inward rectifier potassium channel 11.
- Target
- ATP-sensitive inward rectifier potassium channel 11
- Mechanism
- Potassium channel, inwardly rectifying, subfamily J, member 11 opener
pharma · SH2B1 Deficiency Obesity · Prader-Willi Syndrome · SLNO
SOLENO THERAPEUTICS
SOLENO THERAPEUTICS INC
SOLENO THERAPEUTICS drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Redwood City, USA HQ
199 Employees
Public company Type
SLNO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Redwood City, USA
- Employees
- 199
- Programs
- 2
- Drugs
- 4
- Patents
- 0
SOLENO THERAPEUTICS pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
SOLENO THERAPEUTICS drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
diazoxide choline
Nervous system (N07)US regulatory status: approved.
-
Development asset linked to SOLENO THERAPEUTICS in public FDA and regional records.
-
Development asset linked to SOLENO THERAPEUTICS in public FDA and regional records.